M Fava

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication
    M Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Mol Psychiatry 15:856-67. 2010
  2. pmc Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo
    P F Sullivan
    Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 7264, USA
    Mol Psychiatry 14:359-75. 2009
  3. doi A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)
    Maurizio Fava
    Clinical Trials and Network Institute CTNI, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 81:87-97. 2012
  4. pmc A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression
    Nhi Ha T Trinh
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, USA
    BMC Psychiatry 11:166. 2011
  5. pmc A study of the effectiveness of telepsychiatry-based culturally sensitive collaborative treatment of depressed Chinese Americans
    Albert Yeung
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Psychiatry 11:154. 2011
  6. pmc Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Ann Gen Psychiatry 9:10. 2010
  7. ncbi Depression with physical symptoms: treating to remission
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 64:24-8. 2003
  8. ncbi Augmenting antidepressants with folate: a clinical perspective
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:4-7. 2007
  9. ncbi Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, and Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
    Ann Clin Psychiatry 19:153-9. 2007
  10. ncbi The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychother Psychosom 72:115-27. 2003

Detail Information

Publications148 found, 100 shown here

  1. pmc The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication
    M Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Mol Psychiatry 15:856-67. 2010
    ..Further investigation is warranted of distinct family aggregation, risk factors and treatment response. Consideration should also be given to including irritability as a nondiagnostic symptom of adult MDD in DSM-V and ICD-11...
  2. pmc Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo
    P F Sullivan
    Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 7264, USA
    Mol Psychiatry 14:359-75. 2009
    ..With the integrated replication effort, we present a specific hypothesis for further studies...
  3. doi A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)
    Maurizio Fava
    Clinical Trials and Network Institute CTNI, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 81:87-97. 2012
    ..We assessed the efficacy of low-dose aripiprazole added to antidepressant therapy (ADT) in major depressive disorder (MDD) patients with inadequate response to prior ADT...
  4. pmc A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression
    Nhi Ha T Trinh
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, USA
    BMC Psychiatry 11:166. 2011
    ..To address these issues, we implemented a multi-component intervention for Asian American and Latino American primary care patients with depression at Massachusetts General Hospital (MGH)...
  5. pmc A study of the effectiveness of telepsychiatry-based culturally sensitive collaborative treatment of depressed Chinese Americans
    Albert Yeung
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Psychiatry 11:154. 2011
    ..The current study builds on this prior research by incorporating telemedicine technology into the CSCT model...
  6. pmc Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
    Huaiyu Yang
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Ann Gen Psychiatry 9:10. 2010
    ..Future studies are needed to further explore the relationship between residual sleep disturbance and relapse in MDD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00427128...
  7. ncbi Depression with physical symptoms: treating to remission
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 64:24-8. 2003
    ..Treating both psychological and physical symptoms of depression may lead to a higher percentage of patients reaching remission...
  8. ncbi Augmenting antidepressants with folate: a clinical perspective
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:4-7. 2007
    ....
  9. ncbi Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, and Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
    Ann Clin Psychiatry 19:153-9. 2007
    ..This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue...
  10. ncbi The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Psychother Psychosom 72:115-27. 2003
    ..If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders...
  11. ncbi Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 165:342-51. 2008
    ..The authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients with anxious and nonanxious major depression in Levels 1 and 2 of the STAR*D study...
  12. ncbi Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Psychiatry 59:1052-60. 2006
    ..Insomnia and major depressive disorder (MDD) can coexist. This study evaluated the effect of adding eszopiclone to fluoxetine...
  13. doi Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder
    Maurizio Fava
    Massachusetts General Hospital, Boston, MA 02114, United States
    J Affect Disord 113:263-71. 2009
    ..Using data from a relapse prevention study of duloxetine treatment for adults with major depressive disorder (MDD), we examined demographic- and illness-related variables to identify factors that may predict relapse of MDD...
  14. ncbi Management of depression relapse: re-initiation of duloxetine treatment or dose increase
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, ACC 812, Boston, MA 02114, United States
    J Psychiatr Res 40:328-36. 2006
    ..Patients relapsing on duloxetine 60 mg QD benefited from an increase to 60 mg BID. These duloxetine doses were well tolerated and effective, and appear appropriate for MDD patients requiring treatment of relapse...
  15. ncbi Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Psychopharmacol 22:379-87. 2002
    ....
  16. ncbi Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02214, USA
    J Clin Psychopharmacol 23:365-9. 2003
    ..Immediate switching to reboxetine appears to be a safe and effective treatment for patients with depression who have failed to respond to an adequate dose of fluoxetine...
  17. ncbi Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 64:30-4. 2003
    ..A number of augmentation strategies can be employed to manage fatigue or cognitive/executive dysfunction, but the efficacy of these augmentation strategies must be researched further...
  18. ncbi Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA
    Psychother Psychosom 75:139-53. 2006
    ..g., anxiety, insomnia) may lead to premature discontinuation from monotherapy in the absence of concomitant use of augmenting pharmacological options targeting these symptoms...
  19. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
    ..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine...
  20. ncbi Pharmacological approaches to the treatment of residual symptoms
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Psychopharmacol 20:29-34. 2006
    ..Studies assessing the evaluation and treatment of residual symptoms and side effects will contribute importantly to the optimal acute and long-term management of depression...
  21. ncbi Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 34:1299-308. 2004
    ..Anxious depression, defined as Major Depressive Disorder (MDD) with high levels of anxiety symptoms, may represent a relatively common depressive subtype, with distinctive features...
  22. ncbi A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 66:85-93. 2005
    ....
  23. ncbi Prospective studies of adverse events related to antidepressant discontinuation
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02144, USA
    J Clin Psychiatry 67:14-21. 2006
    ..This article also looks at early prospective studies of antidepressant discontinuation reactions based on spontaneous reports and discusses, while making the case for, prospective studies based on systematic inquiry...
  24. ncbi Daytime sleepiness and insomnia as correlates of depression
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 65:27-32. 2004
    ..Finally, several different treatment options, including antidepressant monotherapy and augmentation of antidepressants with other medications, are explored...
  25. ncbi A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Bulfinch 351, 55 Fruit St, Boston, MA 02114, USA
    Am J Psychiatry 163:1161-72. 2006
    ....
  26. ncbi Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial
    Maurizio Fava
    Depression Clinical and Research Program, The Department of Psychiatry, Massachusetts General Hospital, Boston 02114, and the Department of Psychiatry, University of New Mexico, Albuquerque, USA
    J Clin Psychiatry 67:240-6. 2006
    ..To evaluate the efficacy of short-term treatment with sildenafil citrate in men with serotonin reuptake inhibitor (SRI)-associated erectile dysfunction (ED)...
  27. ncbi What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension
    Maurizio Fava
    Massachusetts General Hospital, Boston, Harvard Medical School, MA 02114, USA
    Can J Psychiatry 51:823-35. 2006
    ..This study was designed to replicate and extend our initial findings in a subsequent, larger cohort of outpatient STAR*D participants with nonpsychotic major depressive disorder (MDD)...
  28. ncbi A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 67:1754-9. 2006
    ..The purpose of the present work is to examine cross-sectionally the prevalence of cognitive and physical side effects of antidepressants during long-term treatment of depression...
  29. ncbi Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA
    Psychother Psychosom 71:195-9. 2002
    ..We evaluated the likelihood of response to reinitiation of fluoxetine treatment in patients relapsing after switching to placebo during a long-term efficacy study of two different dosing regimens of fluoxetine...
  30. ncbi Somatic symptoms, depression, and antidepressant treatment
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 63:305-7. 2002
  31. doi A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA 02114, USA
    J Clin Psychiatry 72:473-9. 2011
    ..In this post hoc analysis of patients with insomnia and comorbid anxious depression, eszopiclone cotherapy with a selective serotonin reuptake inhibitor (SSRI) was compared with placebo cotherapy...
  32. doi Folate in depression: efficacy, safety, differences in formulations, and clinical issues
    Maurizio Fava
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114, USA
    J Clin Psychiatry 70:12-7. 2009
    ..Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy...
  33. ncbi Fenfluramine challenge in unipolar depression with and without anger attacks
    M Fava
    Depression Clinical and Research Program, WACC 812, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA
    Psychiatry Res 94:9-18. 2000
    ....
  34. ncbi New approaches to the treatment of refractory depression
    M Fava
    Department of Psychiatry, Harvard Medical School, Boston, Mass, USA
    J Clin Psychiatry 61:26-32. 2000
    ..The review of treatment options for refractory depression that follows will outline the advantages, disadvantages, and level of support for a number of new treatment strategies...
  35. doi Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 78:91-7. 2009
    ....
  36. ncbi Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Psychopharmacol 22:137-47. 2002
    ..Improvement in overall depression and in associated insomnia was achieved by most patients regardless of baseline insomnia...
  37. ncbi Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial
    Maurizio Fava
    MGH Clinical Trials Network and Institute, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA, USA
    J Clin Psychiatry 72:914-28. 2011
    ..This investigation was performed to assess the efficacy and safety of zolpidem extended-release in patients with insomnia associated with major depressive disorder (MDD)...
  38. doi Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Psychopharmacol 29:222-30. 2009
    ....
  39. ncbi Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, WAC 812, 15 Parkman Street, 02114, Boston, MA, USA
    J Affect Disord 59:119-26. 2000
    ..For this reason, using head-to-head acute treatment comparison, we compared efficacy and tolerability of fluoxetine, sertraline, and paroxetine among depressed patients with high levels of anxiety...
  40. ncbi Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment
    M Fava
    Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 61:863-7. 2000
    ..Also unknown is whether different agents have differential effects. To examine these questions, we assessed weight changes in patients randomly assigned to long-term treatment with fluoxetine, sertraline, or paroxetine...
  41. ncbi Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 62:413-20. 2001
    ..To evaluate the efficacy and safety of mirtazapine in depressed outpatients who have shown nonresponse or intolerance to selective serotonin reuptake inhibitor (SSRI) therapy...
  42. ncbi The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 64:26-9. 2003
    ..These data may suggest that antidepressants that are particularly effective in the treatment of pain and painful physical symptoms may yield higher remission rates in major depressive disorder...
  43. doi Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Psychopharmacol 29:362-7. 2009
    ..Also, there was no apparent change in the incidence of National Cholesterol Education Program-defined abnormal metabolic measures after treatment with aripiprazole...
  44. ncbi Hypochondriacal concerns in depressed outpatients
    C Demopulos
    Depression Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychosom Med 58:314-20. 1996
    ....
  45. doi Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report
    A A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychol Med 40:41-50. 2010
    ..We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial...
  46. ncbi Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D
    William R Yates
    Department of Psychiatry, University of Oklahoma College of Medicine, Tulsa, OK 74135, USA
    Gen Hosp Psychiatry 26:421-9. 2004
    ..A significant percentage of patients with major depressive disorder (MDD) suffer from concurrent general medical conditions (GMCs)...
  47. pmc Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder
    R H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Acta Psychiatr Scand 119:282-9. 2009
    ..We examined clinical correlates of irritability in a confirmatory cohort of Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study participants with major depressive disorder (MDD)...
  48. ncbi Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
    Am J Psychiatry 164:739-52. 2007
    ..Cognitive therapy was compared with medication augmentation and switch strategies...
  49. pmc Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis
    Bradley N Gaynes
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Ann Fam Med 5:126-34. 2007
    ....
  50. ncbi Outcome definitions and predictors in depression
    J Tedlow
    Depression Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychother Psychosom 67:266-70. 1998
    ..We therefore wanted to investigate possible relationships between baseline severity of depression and anxiety, and different definitions of outcome among outpatients with major depressive disorder undergoing antidepressant treatment...
  51. ncbi Indicators of pretreatment suicidal ideation in adults with major depressive disorder
    D W Morris
    Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
    Acta Psychiatr Scand 121:480-4. 2010
    ..The purpose of this report is to identify sociodemographic and clinical features that are associated with SI in major depressive disorder (MDD) patients prior to treatment with a selective serotonin reuptake inhibitor...
  52. ncbi Timing of onset of antidepressant response with fluoxetine treatment
    A A Nierenberg
    Depression and Clinical Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 157:1423-8. 2000
    ..The purpose of this study was to assess the time until onset of antidepressant response with fluoxetine treatment...
  53. ncbi Medication augmentation after the failure of SSRIs for depression
    Madhukar H Trivedi
    Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
    N Engl J Med 354:1243-52. 2006
    ..Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach...
  54. ncbi Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    Arch Gen Psychiatry 65:870-80. 2008
    ..Little is known about selecting among second-step medications for major depressive disorder after intolerance or lack of remission with an initial selective serotonin reuptake inhibitor...
  55. ncbi Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression
    D Mischoulon
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman St, WAC 812, Boston, MA 02114, USA
    J Psychosom Res 49:183-7. 2000
    ..We wished to determine whether anemia or macrocytosis predict hypofolatemia, low B12, or refractoriness to antidepressants...
  56. ncbi Course and treatment of atypical depression
    A A Nierenberg
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 59:5-9. 1998
    ..A review and critique of the relevant literature on atypical depression will be presented...
  57. ncbi Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day
    R H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, WACC 812, 15 Parkman Street, Boston, MA 02114, USA
    Acta Psychiatr Scand 108:432-8. 2003
    ..Factors moderating response to these next-step interventions are not well-studied...
  58. ncbi Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study
    Michael E Thase
    Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    CNS Spectr 11:93-102. 2006
    ..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms...
  59. ncbi Major depressive disorder with anger attacks and cardiovascular risk factors
    Renerio Fraguas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, USA
    Int J Psychiatry Med 37:99-111. 2007
    ..Depression and anger have been separately associated with cardiovascular risk factors. We investigated if major depressive disorder (MDD) with concomitant anger attacks was associated with cardiovascular risk factors...
  60. ncbi The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
    Maurizio Fava
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    J Clin Psychiatry 65:521-30. 2004
    ..It was hypothesized that resolution of both psychological and physical symptoms of depression would predict a higher percentage of patients achieving remission...
  61. ncbi T3 blood levels and treatment outcome in depression
    D V Iosifescu
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Psychiatry Med 31:367-73. 2001
    ..CONCLUSION: Abnormal T3-RU levels are rather uncommon in outpatient depression and do not correlate with the response to antidepressant treatment or lack thereof...
  62. ncbi Folate, vitamin B12, and homocysteine in major depressive disorder
    M Fava
    Depression Clinical and Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA
    Am J Psychiatry 154:426-8. 1997
    ..The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients...
  63. ncbi Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
    Madhukar H Trivedi
    Department of Psychiatry, University of Texas Southwestern Medical Center, Exchange Park Express, American General Tower, 6363 Forest Park Rd, Suite 1300, Dallas, TX 75390 9119, USA
    Am J Psychiatry 163:28-40. 2006
    ....
  64. ncbi Acceptability of second-step treatments to depressed outpatients: a STAR*D report
    Stephen R Wisniewski
    Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 164:753-60. 2007
    ..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches...
  65. ncbi Insured and non-insured depressed outpatients: how do they compare?
    Ira M Lesser
    Department of Psychiatry, Harbor UCLA Medical Center, The Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
    Ann Clin Psychiatry 19:73-82. 2007
    ....
  66. ncbi Personality disorders and the trimensional personality questionnaire factors in major depressive disorder
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Nerv Ment Dis 193:747-50. 2005
    ..Certain temperament traits, especially HA and NS, appear to be associated with specific patterns of personality clusters among depressed patients...
  67. ncbi Augmentation and combination strategies in treatment-resistant depression
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 62:4-11. 2001
    ..Further studies are clearly needed to evaluate the comparative efficacy and tolerability of these different approaches in treatment-resistant depressions...
  68. ncbi Personality disorders and depression
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Psychol Med 32:1049-57. 2002
    ....
  69. doi Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial
    Edward S Friedman
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Depress Anxiety 26:612-21. 2009
    ..But nonresponse can include depression that worsened over the course of treatment, an outcome that has received scant attention...
  70. pmc A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders
    A Eden Evins
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 28:660-6. 2008
    ..Given the high abstinence rate achieved with CBT plus NRT, a ceiling effect related to the high level of intervention received by all subjects may have prevented an adequate test of bupropion...
  71. doi Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression
    Robert H Howland
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Ann Clin Psychiatry 20:209-18. 2008
    ..To identify putative demographic and clinical variables that correlate with antidepressant response to the SNRI duloxetine in major depression...
  72. doi Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
    J Affect Disord 117:63-73. 2009
    ..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI...
  73. pmc Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants
    Roy H Perlis
    Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Arch Gen Psychiatry 65:882-92. 2008
    ....
  74. ncbi Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
    Control Clin Trials 25:119-42. 2004
    ..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments...
  75. ncbi The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)
    A H Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA WAC 812, USA
    Acta Psychiatr Scand 110:465-70. 2004
    ....
  76. ncbi The anxiety sensitivity index: item analysis and suggestions for refinement
    M A Blais
    Inpatient Psychiatry Service, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Pers Assess 77:272-94. 2001
    ..The 11-item ASI appears to tap 2 primary aspects of anxiety sensitivity: fears of somatic sensations of anxiety and fears of loss of mental control. Suggestions for further development of the ASI are offered...
  77. ncbi Treatment resistant depression and axis I co-morbidity
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Psychol Med 31:1223-9. 2001
    ..In fact, the only statistical difference showed non-TRD patients with higher co-morbidity rates...
  78. ncbi Tryptophan depletion in SSRI-recovered depressed outpatients
    M K Spillmann
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Psychopharmacology (Berl) 155:123-7. 2001
    ..No other predicting or mediating factors were identified, although the variable "history of response pattern to medication" deserves further study...
  79. ncbi Management of major depression in the primary care setting
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychother Psychosom 70:103-7. 2001
    ..We wished to determine how PCPs in a community clinic setting initially manage patients newly diagnosed with major depression...
  80. ncbi Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 45:476-81. 2000
    ..To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) are ineffective...
  81. ncbi Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 154:1760-2. 1997
    ..The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration...
  82. ncbi An open trial of oral sildenafilin antidepressant-induced sexual dysfunction
    M Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA
    Psychother Psychosom 67:328-31. 1998
    ..The goal of our study was to evaluate its efficacy in a small sample of outpatients with antidepressant-induced sexual dysfunction...
  83. ncbi Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report
    Patrick J McGrath
    Department of Psychiatry, College of Physicians and Surgeons of Columbia University and New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 69:1847-55. 2008
    ....
  84. ncbi Effect of age at onset on the course of major depressive disorder
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, CA 92093, USA
    Am J Psychiatry 164:1539-46. 2007
    ..This report assesses whether age at onset defines a specific subgroup of major depressive disorder in 4,041 participants who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study...
  85. ncbi Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
    Am J Psychiatry 163:1905-17. 2006
    ..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial...
  86. ncbi Family history of depression and therapeutic outcome: findings from STAR*D
    Mustafa M Husain
    Department of Psychiatry, University of Texas Southwestern Medical School, Dallas, TX 75390 8898, USA
    J Clin Psychiatry 70:185-95. 2009
    ....
  87. ncbi What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression
    Bradley N Gaynes
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Psychiatr Serv 60:1439-45. 2009
    ..STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed...
  88. ncbi Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset
    Dost Ongur
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, WACC 812, Boston, MA 02114, USA
    Psychother Psychosom 74:173-8. 2005
    ..We used the Tridimensional Personality Questionnaire (TPQ) to study the relationship between temperamental traits and comorbid anxiety disorders as well as age of onset of major depressive disorder (MDD) in 263 patients with MDD...
  89. ncbi Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    N Engl J Med 354:1231-42. 2006
    ..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another...
  90. ncbi Factors that differentiate early vs. later onset of major depression disorder
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, 9500 Gilman Dr, 0603R, La Jolla, CA 92093, USA
    Psychiatry Res 129:127-40. 2004
    ..Thus, pre-adulthood onset MDD is a particularly severe and chronic condition...
  91. ncbi Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction
    H G Nurnberg
    1Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM 87131 52886, USA
    Int J Impot Res 19:167-75. 2007
    ..05) or remained stable (sildenafil/sildenafil). In men with MDD-R who maintained antidepressant adherence, 81% of double-blind partial and non-responders treated with open-label sildenafil responded fully...
  92. ncbi Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychol Med 34:555-61. 2004
    ..The goal of this study was to examine whether CBT would help maintain attributional style changes experienced by patients during acute phase fluoxetine treatment...
  93. ncbi A survey of prescribing preferences in the treatment of refractory depression: recent trends
    R Kornbluh
    McLean Hospital, Belmont, MA, USA
    Psychopharmacol Bull 35:150-6. 2001
    ..Further research is necessary to elucidate the factors that influence clinicians' reasoning for selecting one strategy over another...
  94. ncbi Pain in depression: STAR*D study findings
    Mustafa M Husain
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 8898, USA
    J Psychosom Res 63:113-22. 2007
    ..Pain complaints commonly accompany major depressive disorder (MDD). However, whether patients with MDD and pain complaints differ from those without pain complaints is not well studied...
  95. ncbi Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report
    Diane Warden
    Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9086, USA
    Am J Psychiatry 164:1189-97. 2007
    ..The purpose of this study was to identify the pretreatment predictors of attrition during acute treatment with citalopram in a large, "real world" clinical trial...
  96. ncbi Depression and folate status in the US Population
    Martha S Morris
    Jean Mayer United States Department of Agriculture, Human Nutrition Research Center on Aging, Tufts University, Boston, Mass, USA
    Psychother Psychosom 72:80-7. 2003
    ..These relationships have not been demonstrated in general populations. This study examined associations between depression and folate status indicators in an ethnically diverse general US population sample aged 15-39 years...
  97. ncbi Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial
    H George Nurnberg
    Department of Psychiatry, Health Sciences Center, University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, NM 87131 5288, USA
    JAMA 289:56-64. 2003
    ..Sexual dysfunction is a common adverse effect of antidepressants that frequently results in treatment noncompliance...
  98. doi Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome
    Robert H Howland
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213, United States
    Drug Alcohol Depend 99:248-60. 2009
    ....
  99. ncbi Melancholia and axis II comorbidity
    Joyce Tedlow
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    Compr Psychiatry 43:331-5. 2002
    ....
  100. ncbi A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment
    David Mischoulon
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
    Depress Anxiety 19:43-50. 2004
    ..Our study suggests that the rate of negative outcomes with nefazodone is no different whether patients have recently failed an SSRI...
  101. doi An open study of aripiprazole and escitalopram for psychotic major depressive disorder
    John D Matthews
    Inpatient Psychiatric Services, Harvard Medical School, Massachusetts General Hospital Boston, MA 02114, USA
    J Clin Psychopharmacol 29:73-6. 2009
    ..This 7-week trial assessed the efficacy and tolerability of aripiprazole combined with escitalopram in the acute treatment of major depressive disorder, with psychotic features (MD-Psy)...

Research Grants13

  1. 3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Maurizio Fava; Fiscal Year: 2010
    ....
  2. Drug Discovery Group for Nicotine Dependence Treatment
    Maurizio Fava; Fiscal Year: 2007
    ..Each organization will make a unique contribution of personnel and resources to the implementation and success of the project. ..
  3. Placebo-Controlled Study of SAMe vs.Escitalopram in MDD
    Maurizio Fava; Fiscal Year: 2006
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  4. Placebo-Controlled Study of SAMe vs.Escitalopram in MDD
    Maurizio Fava; Fiscal Year: 2005
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  5. Placebo-Controlled Study of SAMe vs.Escitalopram in MDD
    Maurizio Fava; Fiscal Year: 2004
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  6. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  7. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2002
    ....
  8. Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder
    Maurizio Fava; Fiscal Year: 2007
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  9. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2001
    ....
  10. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2000
    ....
  11. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 1999
    ....